Advertisement

Topics

AbbVie's Mavyret for HCV gets FDA nod

05:15 EDT 7 Aug 2017 | SmartBrief

AbbVie's breakthrough therapy Mavyret, or glecaprevir and pibrentasvir, has been approved by the FDA as an eight-week regimen -More

Original Article: AbbVie's Mavyret for HCV gets FDA nod

NEXT ARTICLE

More From BioPortfolio on "AbbVie's Mavyret for HCV gets FDA nod"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...